logo
Sanuwave Health reports Q2 EPS 1c vs $1.77 last year

Sanuwave Health reports Q2 EPS 1c vs $1.77 last year

Reports Q2 revenue $10.2M vs $7.2M last year. 'We're pleased to have put up strong results for Q2 and to have achieved 51% revenue growth in the first six months of 2025 vs the same period in 2024 ,' said Morgan Frank, CEO. 'We sold 214 UltraMIST systems in the first six months of this year, more than we did in the full year of 2023 and an increase of 86% versus same period in 2024. Q1 and Q2 have been spent building and reshaping our sales and commercial operations teams, and as of mid July, the Company achieved full national sales coverage for the first time in my tenure as CEO. If Q1 and Q2 were the quarters of 'max disruption' Q3 is expected to be the quarter of 'max construction' as the Company builds up momentum around our new sales and marketing practices (including the launch of our first concerted marketing program) with an aim to set us up for breakout performance in Q4 2025 and 2026. The energy at our sales and commercial operations national meeting a couple of weeks ago was palpable. I think we're all looking forward to seeing what Sanuwave can become as it starts firing on all cylinders.'
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights

Business Wire

time23 minutes ago

  • Business Wire

Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights

LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ('Spectrum' or 'the Company') (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: DEADLINE: September 24, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Spectrum's Pinnacle Study of poziotinib for the treatment of lung cancer was less positive than it portrayed to investors. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

QQQ ETF News, 8/12/2025
QQQ ETF News, 8/12/2025

Business Insider

time42 minutes ago

  • Business Insider

QQQ ETF News, 8/12/2025

How is QQQ stock faring? The Invesco QQQ ETF has risen 2.3% over the past five days and is up 12.68% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $634.25 for the QQQ ETF implies an upside potential of 10.7%. Currently, QQQ's five holdings with the highest upside potential are Charter Communications (CHTR), Atlassian Corporation (TEAM), Lululemon Athletica (LULU), Trade Desk (TTD), and Adobe Systems (ADBE). Meanwhile, its top holdings with the greatest downside potential are Palantir Technologies (PLTR), Tesla Motors (TSLA), and Fastenal (FAST). Revealingly, QQQ ETF's Smart Score is seven, implying that this ETF is likely to perform in line with the market. Power up your ETF investing with TipRanks. Discover the ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.

Cargill's Revenue Falls to 4-Year Low Amid Declining Crop Prices
Cargill's Revenue Falls to 4-Year Low Amid Declining Crop Prices

Bloomberg

timean hour ago

  • Bloomberg

Cargill's Revenue Falls to 4-Year Low Amid Declining Crop Prices

Cargill Inc. 's revenue declined to the lowest in four years as the largest private company in the US continues to restructure in the face of declining crop prices and a shrinking American cattle herd. The Minneapolis-based company posted revenue of $154 billion in the year ended May 31, according to an annual report posted on its website. That's down from about $160 billion a year earlier and the lowest since 2021, when revenue was reported at $134 billion.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store